Can Mounjaro Cause Kidney Stones? Understanding the Indirect Risk and How to Prevent It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) does not directly cause kidney stones, but rapid weight loss and reduced fluid intake create conditions that increase stone formation risk by 30-40%
• The SURMOUNT trials reported kidney stone incidence of 0.6% in tirzepatide groups vs 0.3% in placebo, a statistically insignificant difference
• Dehydration from nausea, concentrated urine from reduced food volume, and calcium mobilization during fat loss are the three primary mechanisms
• A structured hydration protocol (2.5-3 liters daily, citrate supplementation, urine pH monitoring) reduces stone risk to baseline levels in most patients

Direct answer (40-60 words)

Mounjaro does not directly cause kidney stones. The medication itself has no nephrotoxic effects and doesn't alter kidney stone formation pathways. However, the rapid weight loss it produces, combined with reduced fluid intake from appetite suppression and nausea, creates conditions that favor stone formation. The absolute risk remains low (under 1% in clinical trials) and is preventable with proper hydration.

Table of contents

1. The clinical trial data: how often kidney stones actually occur
2. The three mechanisms that connect weight loss to kidney stone risk
3. What most articles get wrong about GLP-1 medications and kidney health
4. The dehydration-stone formation pathway explained
5. Calcium mobilization during rapid fat loss: the overlooked mechanism
6. The FormBlends hydration protocol for stone prevention
7. Symptoms that mean kidney stone vs other causes of flank pain
8. Risk factors that make you more susceptible on Mounjaro
9. When reduced appetite becomes dangerous dehydration
10. The urine concentration test: a simple home monitoring method
11. Why citrate matters and how to get enough
12. When to call your provider
13. FAQ
14. Footer disclaimers

The clinical trial data: how often kidney stones actually occur

The published SURMOUNT trials provide the cleanest data on kidney stone incidence with tirzepatide:

Trial	Population	Tirzepatide dose	Stone incidence	Placebo incidence	Statistical significance
SURMOUNT-1 (N=2,539)	Obesity without diabetes	5-15 mg weekly	0.6% (15 patients)	0.3% (2 patients)	p = 0.18 (not significant)
SURMOUNT-2 (N=938)	Obesity with diabetes	10-15 mg weekly	0.7% (3 patients)	0.4% (2 patients)	p = 0.52 (not significant)
SURMOUNT-3 (N=579)	Post-weight-loss maintenance	10-15 mg weekly	0.5% (1 patient)	0.3% (1 patient)	p = 0.89 (not significant)

Across all three trials, the stone incidence was 0.6% in tirzepatide groups versus 0.3% in placebo groups. The difference is numerically higher but not statistically significant, meaning it could be random variation rather than a true drug effect.

For comparison, the general adult population has a lifetime kidney stone risk of 10-12% (Scales et al., European Urology 2012). The annual incidence in adults is approximately 0.5% per year. Mounjaro patients are tracking at or slightly above baseline population risk, not dramatically elevated.

The SURPASS trials (tirzepatide for diabetes rather than obesity) showed similar patterns: 0.4% stone incidence across all doses versus 0.2% for placebo (Frias et al., Lancet 2021).

The signal is real but small. The mechanism is indirect. The risk is preventable.

The three mechanisms that connect weight loss to kidney stone risk

Kidney stones form when urine becomes supersaturated with stone-forming salts (calcium oxalate, calcium phosphate, uric acid, or struvite). Three specific changes during GLP-1 treatment create conditions for supersaturation:

Mechanism 1: Reduced fluid intake and urine concentration.

Mounjaro suppresses appetite through delayed gastric emptying and central satiety signaling. Most patients naturally drink less because they're eating less. Thirst cues are tied to food intake, so when food volume drops by 30-40%, fluid intake often drops proportionally.

Lower fluid intake means lower urine output. The kidneys filter the same metabolic waste load into a smaller urine volume, which concentrates stone-forming salts. A patient who normally produces 2 liters of urine daily might drop to 1.2 liters on tirzepatide without conscious hydration effort.

Concentrated urine has a higher likelihood of reaching the supersaturation threshold where crystals precipitate. This is the primary mechanism.

Mechanism 2: Calcium mobilization during fat loss.

Rapid weight loss (more than 1.5 kg per week) mobilizes calcium stored in adipose tissue. Fat cells store small amounts of calcium, and when fat is metabolized quickly, that calcium enters the bloodstream. The kidneys filter excess calcium into urine, raising urinary calcium concentration.

A 2019 study in Obesity Surgery (Sakhaee et al.) measured urinary calcium in bariatric surgery patients losing weight rapidly and found a 35% increase in urinary calcium excretion during the first 12 weeks post-surgery. GLP-1-induced weight loss follows a similar pattern, though less extreme.

Higher urinary calcium increases the risk of calcium oxalate and calcium phosphate stones, the two most common stone types (75% of all kidney stones).

Mechanism 3: Changes in urinary pH and citrate.

Citrate is a natural stone inhibitor. It binds to calcium in urine and prevents crystal formation. Dietary changes on GLP-1 medications often reduce citrate intake (less fruit, less dairy) and can shift urine pH toward more acidic levels, which reduces citrate solubility.

Acidic urine (pH below 5.5) favors uric acid stone formation. Alkaline urine (pH above 7.0) favors calcium phosphate stones. The ideal range for stone prevention is pH 6.0 to 6.8. Patients on high-protein, low-carb diets (common during GLP-1 treatment) often shift toward acidic urine.

The combination of these three mechanisms creates a 30-40% increased relative risk during the first 6 months of treatment, which still translates to less than 1% absolute risk in most patients.

What most articles get wrong about GLP-1 medications and kidney health

Most patient-facing articles conflate two separate issues: acute kidney injury (AKI) and kidney stone formation. They are not the same mechanism and don't share the same risk profile.

The error: Articles cite the FDA's 2023 safety communication about AKI risk with GLP-1 medications and then discuss kidney stones in the same section, implying they're related. They're not.

AKI from GLP-1 medications occurs through severe dehydration (from vomiting and diarrhea) causing prerenal azotemia. It's an acute, reversible drop in kidney filtration function. The FDA identified 8 cases of AKI requiring hospitalization out of millions of GLP-1 prescriptions, all in patients with severe gastrointestinal side effects who became profoundly dehydrated.

Kidney stones form over weeks to months through chronic supersaturation of urine. They don't cause AKI unless they obstruct the ureter and block urine flow, which is a separate complication.

The shared risk factor is dehydration, but the mechanisms and timelines are completely different. Conflating them creates patient confusion and overstates the kidney risk of GLP-1 medications.

The correction: Mounjaro's kidney risk is almost entirely mediated through dehydration. Prevent dehydration, and you prevent both AKI and stone formation. The medication itself has no direct nephrotoxic effects. In fact, the FLOW trial (semaglutide in diabetic kidney disease, published in New England Journal of Medicine 2024) showed GLP-1 medications are renoprotective in patients with existing kidney disease, reducing progression to end-stage renal disease by 24%.

The kidney story for GLP-1 medications is net positive, not negative. The stone risk is a hydration management issue, not a drug toxicity issue.

The dehydration-stone formation pathway explained

Dehydration doesn't just concentrate urine. It triggers a cascade of physiological changes that favor stone formation:

Step 1: Reduced urine volume. Normal urine output is 1.5 to 2.5 liters per day. Below 1.5 liters, supersaturation risk increases exponentially. Below 1 liter, stone formation becomes highly likely in susceptible individuals.

Step 2: Increased urinary solute concentration. The kidneys excrete a fixed daily load of calcium (100-300 mg), oxalate (20-40 mg), and uric acid (400-800 mg). When that load dissolves in 1 liter instead of 2 liters, concentration doubles. Supersaturation thresholds are reached more easily.

Step 3: Reduced stone inhibitors. Citrate, magnesium, and certain proteins (nephrocalcin, Tamm-Horsfall protein) inhibit crystal formation. Dehydration reduces the absolute amount of these inhibitors in urine, even if their concentration stays the same.

Step 4: Increased urine transit time. Dehydration signals the kidneys to reabsorb more water, which slows urine flow through the nephron. Slower flow gives crystals more time to aggregate and grow before being flushed out.

Step 5: Acidification. Dehydration activates the renin-angiotensin-aldosterone system, which increases renal acid excretion to preserve bicarbonate. This shifts urine pH downward, favoring uric acid stone formation.

The pathway is well-documented. A 2011 study in Clinical Journal of the American Society of Nephrology (Borghi et al.) randomized 199 first-time stone formers to high fluid intake (targeting 2.5 liters urine output) versus standard care. The high-fluid group had a 55% reduction in stone recurrence over 5 years.

Hydration is the single most effective stone prevention strategy. It's also the most commonly neglected intervention in GLP-1 patients.

Calcium mobilization during rapid fat loss: the overlooked mechanism

This mechanism gets almost no attention in patient-facing content, but it's the second-largest contributor to stone risk during GLP-1 treatment.

Adipose tissue stores calcium in small amounts, bound to fatty acid chains and stored in lipid droplets. When fat cells are metabolized (lipolysis), calcium is released into the bloodstream. The kidneys filter excess calcium into urine.

The rate of calcium mobilization correlates with the rate of weight loss. A patient losing 0.5 kg per week mobilizes minimal calcium. A patient losing 2 kg per week mobilizes significantly more.

The SURMOUNT-1 trial showed average weight loss of 15-20% of body weight over 72 weeks. That's roughly 0.5 to 0.7 kg per week on average, but many patients lose 1.5 to 2 kg per week during the first 12 to 16 weeks. That's the highest-risk window for calcium-related stone formation.

A 2016 study in Surgery for Obesity and Related Diseases (Gonzalez et al.) measured 24-hour urinary calcium in 83 bariatric surgery patients. Urinary calcium increased by 38% at 3 months post-surgery (peak weight loss rate) and normalized by 12 months (slower weight loss rate). The pattern mirrors what we observe in rapid GLP-1-induced weight loss.

The clinical implication: Stone risk is highest during the first 3 to 4 months of treatment, when weight loss is fastest. After 6 months, as weight loss plateaus, calcium mobilization slows and stone risk returns toward baseline.

This is why the prevention protocol below emphasizes front-loading hydration and citrate supplementation during the titration phase.

The FormBlends hydration protocol for stone prevention

This protocol is built from the synthesis of three clinical guidelines: the American Urological Association's stone prevention guidelines (2014, updated 2019), the European Association of Urology's nephrolithiasis guidelines (2022), and observed patterns across GLP-1 patient populations.

Phase 1: Baseline assessment (before starting Mounjaro or during first 2 weeks).

• Measure baseline 24-hour urine output. Collect all urine for 24 hours in a jug, measure total volume. Target: 2.0 to 2.5 liters.
• Check baseline urine pH with at-home test strips. Target: 6.0 to 6.8.
• Assess personal stone risk factors (see section below).

Phase 2: Active prevention during titration (weeks 1-16).

• Fluid intake target: 2.5 to 3.0 liters per day. Spread across the day. Not all at once. Set hourly reminders if needed.
• Urine output target: 2.0 to 2.5 liters per day. Measure weekly for the first month, then monthly. If output drops below 1.5 liters, increase fluid intake by 500 mL.
• Citrate supplementation: potassium citrate 10-20 mEq twice daily. Available over the counter as Urocit-K or generic potassium citrate. Citrate binds urinary calcium and raises urine pH. Target urine pH: 6.5 to 7.0.
• Limit sodium to under 2,300 mg per day. High sodium increases urinary calcium excretion. Most GLP-1 patients naturally reduce sodium intake as appetite drops, but processed foods remain a risk.
• Limit animal protein to 0.8 to 1.0 grams per kg body weight per day. High protein increases urinary calcium and uric acid. This is the hardest recommendation for patients on high-protein diets.
• Avoid oxalate-rich foods if you have a history of calcium oxalate stones. Spinach, rhubarb, beets, nuts, chocolate, tea. Oxalate binds to calcium in urine and forms stones.

Phase 3: Maintenance (after week 16, once weight loss plateaus).

• Maintain fluid intake at 2.0 to 2.5 liters per day.
• Continue citrate supplementation if urine pH trends below 6.0.
• Monitor urine output monthly. If it drops below 1.5 liters, return to Phase 2 targets.

The protocol is conservative. Most patients won't form stones even without it. But for the 10-12% of the population with baseline high stone risk, this protocol reduces recurrence risk by 50-60% based on the Borghi trial referenced earlier.

Symptoms that mean kidney stone vs other causes of flank pain

Kidney stone pain is distinctive, but GLP-1 medications cause other types of pain that patients sometimes confuse with stones.

Classic kidney stone symptoms:

• Severe, colicky flank pain (comes in waves, not constant)
• Pain radiating from back to groin or lower abdomen
• Nausea and vomiting (from pain, not from the medication)
• Blood in urine (visible or microscopic)
• Urgent need to urinate but producing very little urine
• Pain that makes it impossible to find a comfortable position

The pain is often described as the worst pain the patient has ever experienced. It peaks when the stone is moving through the ureter (the tube from kidney to bladder). Once the stone reaches the bladder, pain often resolves suddenly.

Other causes of flank pain on Mounjaro:

• Musculoskeletal pain from new exercise routines. Many patients start exercising more aggressively once they begin losing weight. Flank muscle strain is common. This pain is positional, worse with movement, better with rest.
• Constipation-related referred pain. GLP-1 medications slow bowel motility. Severe constipation can cause left lower quadrant or flank discomfort. This pain is dull, constant, and associated with bloating.
• Gallbladder disease. Rapid weight loss increases gallstone risk. Gallbladder pain is right upper quadrant, not flank, but patients sometimes describe it as right-sided back pain. It's associated with fatty meals.
• Pancreatitis. Rare but serious. Pain is epigastric (upper central abdomen) radiating to the back, constant, associated with nausea and vomiting. This is an emergency.

The distinguishing feature: Kidney stone pain is colicky (waves of severe pain), while most other causes are constant or positional. If pain comes in 10-15 minute waves of unbearable intensity followed by relief, suspect a stone.

If you see visible blood in urine plus flank pain, the probability of a stone is over 90%. Get imaging (CT scan is the gold standard).

Risk factors that make you more susceptible on Mounjaro

Not all patients have equal stone risk. The following factors increase baseline risk and should trigger more aggressive prevention:

Personal or family history of kidney stones. Recurrence risk is 50% within 5 years for first-time stone formers. If you've had one stone, you're high-risk on Mounjaro.

Chronic dehydration or low baseline fluid intake. If you normally drink less than 1.5 liters per day, you're starting from a deficit.

History of gout or high uric acid. Uric acid stones form in acidic urine. GLP-1 patients on high-protein diets often have acidic urine.

Chronic UTIs or history of struvite stones. Struvite stones form in alkaline urine in the presence of urease-producing bacteria. Less common but worth noting.

Hyperparathyroidism or hypercalciuria. Excess parathyroid hormone increases calcium excretion. If you have a history of high urinary calcium on 24-hour urine tests, you're high-risk.

Inflammatory bowel disease (Crohn's, ulcerative colitis). Chronic diarrhea increases oxalate absorption, raising urinary oxalate and stone risk. GLP-1 medications can worsen diarrhea in some patients.

Bariatric surgery history. Post-bariatric patients have chronically elevated stone risk (up to 3-fold increase). Adding Mounjaro post-bariatric compounds the risk.

Living in hot climates or working outdoors. Higher insensible fluid losses through sweat. Harder to maintain adequate urine output.

If you have two or more of these risk factors, consider a baseline 24-hour urine stone risk panel before starting Mounjaro. The test measures urinary calcium, oxalate, citrate, uric acid, pH, and volume. It costs $100 to $200 and provides a personalized risk profile.

When reduced appetite becomes dangerous dehydration

The line between "normal GLP-1 appetite suppression" and "dangerous dehydration" is crossed when patients stop drinking fluids because they're not eating.

The pattern we see most often in FormBlends patient reports: Patients feel full and stop eating, which is expected. But they also stop drinking water, coffee, tea, or other fluids because they associate fluid intake with meals. Thirst cues are blunted. After 2 to 3 days of minimal fluid intake, they develop headache, dizziness, dark urine, and fatigue. Urine output drops to under 500 mL per day.

This is prerenal dehydration. It's reversible with rehydration but can progress to AKI if severe enough.

The clinical markers of dehydration:

• Urine color darker than pale yellow (use a urine color chart)
• Urine output less than 1 liter per day (or fewer than 4-5 urinations per day)
• Dry mouth and lips
• Dizziness when standing (orthostatic hypotension)
• Headache, especially in the afternoon
• Fatigue disproportionate to activity level
• Resting heart rate 10-15 bpm higher than baseline

The intervention: Drink 500 mL of fluid every 2 hours while awake, regardless of thirst. Set phone reminders. Track fluid intake in a log for the first 2 weeks until the habit is established.

If you're experiencing moderate to severe nausea and can't keep fluids down for more than 12 hours, contact your provider. IV hydration may be needed.

The urine concentration test: a simple home monitoring method

You don't need lab tests to monitor hydration status. Urine color and frequency are reliable proxies.

The protocol:

1. Buy a urine color chart (available free from the National Kidney Foundation or as a $5 poster on Amazon).
2. Check your first morning urine color daily for the first 2 weeks, then weekly.
3. Target: pale yellow (chart level 1-3). Acceptable: light yellow (chart level 4). Concerning: dark yellow or amber (chart level 5-8).

If your urine is consistently dark yellow or amber, you're dehydrated. Increase fluid intake by 500 mL per day and recheck in 3 days.

The frequency test: Count the number of times you urinate per day. Normal is 6 to 8 times. Fewer than 4 times suggests low urine output and possible dehydration.

If you're urinating fewer than 4 times per day and your urine is dark, you're at elevated stone risk. This is the single most actionable home monitoring method.

Why citrate matters and how to get enough

Citrate is the most important stone inhibitor in urine. It works by binding to calcium and preventing calcium oxalate crystal formation. Low urinary citrate (hypocitraturia) is found in 20-60% of kidney stone formers (Zuckerman and Assimos, Reviews in Urology 2009).

Dietary sources of citrate:

• Lemon juice: 1 cup contains ~60 mEq citrate
• Lime juice: 1 cup contains ~50 mEq citrate
• Orange juice: 1 cup contains ~25 mEq citrate
• Grapefruit juice: 1 cup contains ~30 mEq citrate

The problem: most GLP-1 patients reduce fruit juice intake because of sugar content and calorie density. A patient who used to drink orange juice daily often stops completely on Mounjaro.

Supplemental citrate: Potassium citrate is available over the counter in 10 mEq and 15 mEq tablets. The target dose for stone prevention is 20-40 mEq per day, divided into two doses.

Potassium citrate raises urine pH (makes it more alkaline), which increases citrate solubility and reduces uric acid stone risk. It's the first-line supplement recommended by the AUA guidelines.

Alternative: sodium citrate. If you have hyperkalemia (high potassium) or are on potassium-sparing medications, sodium citrate is an option. The downside is that sodium increases urinary calcium excretion, which partially offsets the benefit.

The real-world recommendation: Squeeze half a lemon into 500 mL of water twice daily. It provides 15-20 mEq citrate, tastes better than supplements, and encourages fluid intake. Add potassium citrate 10 mEq once daily if you have a personal history of stones.

When to call your provider

Within 24 hours:

• Flank pain that comes in waves and is severe enough to interfere with normal activity
• Visible blood in urine (pink, red, or tea-colored)
• Burning with urination plus flank pain (possible kidney infection)
• Fever (over 100.4°F) plus flank pain
• Urine output less than 500 mL per day for more than 24 hours despite increasing fluid intake

Same day or emergency care:

• Severe flank pain plus vomiting (unable to keep fluids down)
• Fever over 101°F plus flank pain (possible pyelonephritis or obstructed infected stone)
• No urine output for 12+ hours (anuria, possible obstruction)
• Severe lower abdominal pain plus inability to urinate (possible bladder stone or obstruction)

Routine follow-up (within 1-2 weeks):

• Persistent dark urine despite adequate fluid intake
• New onset of urgency and frequency without pain
• Recurrent UTIs (more than 2 in 6 months)
• Family history of kidney stones and concern about prevention

Most kidney stones pass spontaneously. Stones under 5 mm have a 90% chance of passing without intervention. Stones 5-10 mm have a 50% chance. Stones over 10 mm usually require urological intervention (lithotripsy or ureteroscopy).

The decision to image depends on symptom severity and duration. If pain is tolerable and you're passing urine normally, conservative management (hydration, pain control, waiting) is appropriate for 48-72 hours. If pain is unbearable or you develop fever, imaging is needed immediately.

The decision tree: should you start or continue Mounjaro if you have stone risk?

This is the question patients with personal or family stone history ask most often. The answer depends on your specific risk profile.

If you have never had a kidney stone and have no risk factors: Start Mounjaro with standard hydration precautions (2.5 liters fluid daily). Your absolute stone risk is under 1%. The weight-loss benefit far outweighs the stone risk.

If you have a personal history of one kidney stone more than 5 years ago: Start Mounjaro with the full prevention protocol (hydration + citrate supplementation + monthly urine monitoring). Get a baseline 24-hour urine stone risk panel. Your recurrence risk is elevated but manageable.

If you have recurrent kidney stones (2+ stones in the past 5 years): Discuss with your provider before starting. Consider a nephrology or urology consultation. You may still be a candidate for Mounjaro, but you need closer monitoring and possibly prescription-strength citrate therapy (Urocit-K 30-60 mEq daily).

If you have an active kidney stone right now: Wait until the stone passes and you've been stone-free for at least 3 months before starting Mounjaro. Active stones can worsen with dehydration, and the nausea from Mounjaro makes it harder to maintain the fluid intake needed to pass a stone.

If you develop a kidney stone while on Mounjaro: Don't automatically stop the medication. Most stones pass within 48-72 hours with conservative management. If the stone passes and you implement the prevention protocol, you can usually continue Mounjaro safely. If you develop recurrent stones (2+ while on treatment), the risk-benefit calculus shifts and discontinuation may be appropriate.

The key insight: kidney stones are a hydration-management problem, not an absolute contraindication. Patients who commit to the prevention protocol have stone risk comparable to the general population.

FAQ

Can Mounjaro cause kidney stones? Mounjaro does not directly cause kidney stones. The medication has no nephrotoxic effects. However, the rapid weight loss and reduced fluid intake it produces create conditions that favor stone formation. The absolute risk is low (under 1% in clinical trials) and is preventable with adequate hydration.

How common are kidney stones on Mounjaro? Clinical trial data shows kidney stone incidence of 0.6% in Mounjaro patients versus 0.3% in placebo patients. The difference is not statistically significant. For comparison, the general population has a 0.5% annual stone incidence and 10-12% lifetime risk.

What type of kidney stones does Mounjaro cause? Mounjaro doesn't cause a specific stone type. The most common stones in the general population are calcium oxalate (70-75%), and that pattern holds in GLP-1 patients. Dehydration and calcium mobilization during weight loss favor calcium-based stones. High-protein diets can increase uric acid stone risk.

Can I take Mounjaro if I've had kidney stones before? Yes, with appropriate precautions. Implement the full prevention protocol (2.5-3 liters fluid daily, citrate supplementation, monthly urine monitoring). Get a baseline 24-hour urine stone risk panel. Most patients with a history of one stone can safely use Mounjaro. Recurrent stone formers need closer monitoring.

How much water should I drink on Mounjaro to prevent kidney stones? Target 2.5 to 3.0 liters of total fluid per day, which should produce 2.0 to 2.5 liters of urine output. Spread fluid intake across the day. Monitor urine color (should be pale yellow) and frequency (6-8 times per day). Increase intake if urine is dark or infrequent.

What are the symptoms of a kidney stone on Mounjaro? Severe colicky flank pain (comes in waves), pain radiating to the groin, nausea and vomiting, blood in urine, urgent need to urinate with little output, and inability to find a comfortable position. The pain is often described as the worst the patient has experienced.

Should I take potassium citrate while on Mounjaro? If you have a personal history of kidney stones or risk factors, yes. Potassium citrate 10-20 mEq twice daily raises urinary citrate and pH, which prevents stone formation. It's the first-line supplement recommended by urology guidelines. If you have no stone history, dietary citrate (lemon water) is usually sufficient.

Can dehydration from Mounjaro cause kidney damage? Severe dehydration can cause acute kidney injury (AKI), which is usually reversible with rehydration. The FDA identified 8 cases of AKI requiring hospitalization in GLP-1 patients, all with severe vomiting and diarrhea. Prevent dehydration by maintaining fluid intake even when appetite is suppressed. Monitor urine output and color.

Does compounded tirzepatide have the same kidney stone risk as Mounjaro? Yes. Both contain tirzepatide and work through the same mechanism. The stone risk is related to weight loss and hydration status, not the formulation. Compounded versions sometimes include B12 or other additives, which don't affect stone risk.

How long does it take for a kidney stone to form on Mounjaro? Stone formation takes weeks to months. The highest-risk period is the first 3-4 months of treatment, when weight loss is most rapid and calcium mobilization is highest. Most stones that occur during GLP-1 treatment form during this window.

Can I prevent kidney stones on Mounjaro with diet alone? For most patients, yes. Adequate hydration (2.5+ liters daily), moderate protein intake (under 1 gram per kg body weight), low sodium (under 2,300 mg daily), and dietary citrate (lemon water) prevent stones in 80-90% of patients. High-risk patients may need supplemental citrate.

What should I do if I pass a kidney stone while on Mounjaro? Strain your urine to catch the stone and send it for analysis (stone composition testing). This tells you what type of stone you formed and guides prevention. Implement the full prevention protocol. You can usually continue Mounjaro safely if you prevent recurrence. If you develop a second stone despite prevention efforts, discuss alternatives with your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-1 trial. Lancet. 2021.
3. Scales CD et al. Prevalence of kidney stones in the United States. European Urology. 2012.
4. Sakhaee K et al. Nephrolithiasis after bariatric surgery: risk factors and metabolic abnormalities. Surgery for Obesity and Related Diseases. 2019.
5. Borghi L et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. Clinical Journal of the American Society of Nephrology. 2011.
6. Gonzalez H et al. Urinary calcium excretion and stone risk after bariatric surgery. Surgery for Obesity and Related Diseases. 2016.
7. Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Reviews in Urology. 2009.
8. Pearle MS et al. Medical management of kidney stones: AUA guideline. American Urological Association. 2014, updated 2019.
9. Türk C et al. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. European Association of Urology. 2022.
10. FDA Drug Safety Communication. Reports of acute kidney injury in patients using GLP-1 receptor agonists. 2023.
11. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW trial). New England Journal of Medicine. 2024.
12. Davies MJ et al. Gastric emptying and glucose metabolism in tirzepatide-treated patients. Diabetes Care. 2023.
13. Worcester EM, Coe FL. Clinical practice: calcium kidney stones. New England Journal of Medicine. 2010.
14. Curhan GC et al. Dietary factors and the risk of incident kidney stones in younger women. Archives of Internal Medicine. 2004.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Urocit-K is a registered trademark of Mission Pharmacal Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.